X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10660) 10660
Book Review (3391) 3391
Publication (1067) 1067
Conference Proceeding (21) 21
Book Chapter (20) 20
Dissertation (9) 9
Data Set (2) 2
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8274) 8274
humans (7601) 7601
1st-line treatment (7070) 7070
oncology (6884) 6884
chemotherapy (4559) 4559
female (4478) 4478
male (3379) 3379
middle aged (3364) 3364
aged (3336) 3336
cancer (2998) 2998
adult (2603) 2603
antineoplastic combined chemotherapy protocols - therapeutic use (2486) 2486
open-label (2458) 2458
treatment outcome (2438) 2438
care and treatment (1810) 1810
1st-line therapy (1777) 1777
colorectal cancer (1734) 1734
antineoplastic agents - therapeutic use (1624) 1624
metastasis (1609) 1609
fluorouracil (1466) 1466
colorectal neoplasms - drug therapy (1434) 1434
aged, 80 and over (1420) 1420
phase-iii trial (1399) 1399
disease-free survival (1371) 1371
oxaliplatin (1355) 1355
bevacizumab (1331) 1331
pharmacology & pharmacy (1314) 1314
lung neoplasms - drug therapy (1282) 1282
survival (1281) 1281
mutation (1232) 1232
prognosis (1201) 1201
colorectal neoplasms - pathology (1172) 1172
research (1165) 1165
antineoplastic combined chemotherapy protocols - adverse effects (1148) 1148
trial (1095) 1095
phase-ii trial (1086) 1086
analysis (1084) 1084
carcinoma, non-small-cell lung - drug therapy (1076) 1076
therapy (1073) 1073
drug therapy (1065) 1065
medicine & public health (1048) 1048
double-blind (1035) 1035
leucovorin (1032) 1032
neoplasm metastasis (1008) 1008
phase-iii (981) 981
neoplasm staging (965) 965
clinical trials (961) 961
breast cancer (942) 942
randomized-trial (930) 930
lung cancer (929) 929
multicenter (925) 925
hematology, oncology and palliative medicine (914) 914
retrospective studies (884) 884
combination (875) 875
breast neoplasms - drug therapy (873) 873
gefitinib (873) 873
cancer therapies (865) 865
erlotinib (864) 864
health aspects (859) 859
cell lung-cancer (854) 854
cetuximab (837) 837
1st-line chemotherapy (828) 828
irinotecan (821) 821
patients (812) 812
survival analysis (806) 806
growth-factor receptor (791) 791
fluorouracil - administration & dosage (783) 783
lung cancer, non-small cell (781) 781
capecitabine (773) 773
phase-ii (770) 770
cisplatin (765) 765
metastatic colorectal-cancer (764) 764
survival rate (723) 723
hematology (714) 714
tumors (714) 714
lung neoplasms - pathology (713) 713
antineoplastic combined chemotherapy protocols - administration & dosage (709) 709
adenocarcinoma (695) 695
surgery (686) 686
paclitaxel (669) 669
deoxycytidine - analogs & derivatives (668) 668
animals (666) 666
docetaxel (658) 658
lung neoplasms - genetics (650) 650
epidermal growth factor (648) 648
antineoplastic agents (637) 637
efficacy (623) 623
camptothecin - analogs & derivatives (608) 608
non-small cell lung cancer (608) 608
organoplatinum compounds - administration & dosage (602) 602
protein kinase inhibitors - therapeutic use (595) 595
respiratory system (592) 592
antimitotic agents (591) 591
randomized controlled trials as topic (584) 584
carcinoma, non-small-cell lung - pathology (583) 583
egfr (557) 557
genetic aspects (556) 556
review (556) 556
5-fluorouracil (552) 552
antibodies, monoclonal - therapeutic use (551) 551
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10366) 10366
French (129) 129
German (117) 117
Spanish (15) 15
Italian (11) 11
Polish (8) 8
Russian (7) 7
Hungarian (4) 4
Korean (4) 4
Portuguese (3) 3
Japanese (2) 2
Turkish (2) 2
Chinese (1) 1
Czech (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 01/2018, Volume 19, Issue 1, pp. 139 - 148
Cisplatin-based adjuvant chemotherapy is the standard of care for patients with resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT... 
CELL LUNG-CANCER | SURVIVAL | FORTHCOMING 7TH EDITION | 1ST-LINE TREATMENT | PLACEBO | ESMO CONSENSUS CONFERENCE | THERAPY | ONCOLOGY | TNM CLASSIFICATION | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Pneumonectomy | Protein Kinase Inhibitors - adverse effects | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | China | Adult | Female | Quinazolines - administration & dosage | Chemotherapy, Adjuvant | Gefitinib | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Quinazolines - adverse effects | Cisplatin - adverse effects | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Vinorelbine | Lung cancer, Non-small cell | Care and treatment | Index Medicus
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 4/2015, Volume 20, Issue 2, pp. 207 - 239
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2009, Volume 360, Issue 14, pp. 1408 - 1417
Journal Article
Annals of oncology, ISSN 0923-7534, 2014, Volume 25, Issue 1, pp. 107 - 116
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9561, pp. 559 - 570
Summary Background Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after... 
Internal Medicine | BIOMARKERS | MEDICINE, GENERAL & INTERNAL | BONE-MINERAL DENSITY | CONTINUED TAMOXIFEN | LETROZOLE | SUPERIOR | ADJUVANT TAMOXIFEN | EARLY BREAST-CANCER | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | ANASTROZOLE | Drug Administration Schedule | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local | Selective Estrogen Receptor Modulators - adverse effects | Breast Neoplasms - drug therapy | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Survival Analysis | Postmenopause | Breast Neoplasms - mortality | Female | Aged | Androstadienes - therapeutic use | Tamoxifen - adverse effects | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Evaluation | Dosage and administration | Breast cancer | Tamoxifen | Drug therapy | Research | Health aspects | Death & dying | Cardiovascular system | Design | Statistical analysis | Womens health | Index Medicus | Abridged Index Medicus | drug therapy | pathology | Androstadienes | Local | MEDICIN OCH HÄLSOVETENSKAP | Breast Neoplasms | Aromatase Inhibitors | Selective Estrogen Receptor Modulators | adverse effects | mortality | Neoplasm Recurrence | therapeutic use | MEDICAL AND HEALTH SCIENCES
Journal Article